drugset / Trial / NCT00098228

Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00098228

Phase 2 Completed 686 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.

Timeline

Start
2004-07
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Indacaterol Other / unclassified Inhaled